HoldsUp

Eric Topol

Eric Topol is a medical researcher whose work focuses heavily on the application and evaluation of artificial intelligence and digital technologies across healthcare. His published research explores clinical AI foundation models, dynamic AI evaluation, robotic surgery, and biological aging clocks. Additionally, he has published studies on multi-cancer early detection, COVID-19 treatments, metabolic mechanisms in neurodegeneration, and appraisals of the wellness industry.

59 claims checked on air: 1 context 1 contradicted 11 overstated 41 supported 5 unverified

What they said on air - supported

0:26:26supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.

"preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:26:26)

Large population-based epidemiological studies establish that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (roughly 45% to 55%) of all heart failure cases in clinical practice and community cohorts.

0:26:30supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

GLP-1 receptor agonist drugs reduce systemic inflammation independently of and prior to weight loss.

"We've already seen how GLP-1 drugs do that before any weight loss. So that should work well in people who aren't even obese." (said at 0:26:30)

Randomized clinical trials and translational research demonstrate that GLP-1 receptor agonists exert direct anti-inflammatory effects that occur acutely (even following a single dose) and independently of weight reduction. In human trials, GLP-1 receptor agonism rapidly downregulates reactive oxygen species generation, NF-κB binding, and proinflammatory cytokine expression (including TNF-α, IL-1β, and IL-6) as well as systemic markers such as high-sensitivity C-reactive protein before or in the absence of significant weight loss.

0:26:40supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

GLP-1 receptor agonist medications prevent or improve heart failure with preserved ejection fraction (HFpEF).

"And we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right? GLP-1s prevent that." (said at 0:26:40)

Large phase 3 randomized controlled trials have demonstrated that the GLP-1 receptor agonist semaglutide substantially improves symptoms, physical functioning, and clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). In the STEP-HFpEF and STEP-HFpEF DM trials, once-weekly semaglutide significantly improved Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) scores and 6-minute walk distance while reducing body weight compared with placebo in patients with obesity-related HFpEF. Furthermore, a pooled analysis of 3,743 participants across four randomized trials (STEP-HFpEF, STEP-HFpEF DM, SELECT, and FLOW) showed that semaglutide significantly reduced the risk of worsening heart failure events (HR 0.59, 95% CI 0.41–0.82) and composite cardiovascular death or heart failure events (HR 0.69, 95% CI 0.53–0.89).

0:27:40supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

AI analysis of retinal images can predict coronary artery calcium scores, stroke risk, and heart disease.

"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell if you're going to, um, you know, your calcium score of your heart arteries through your retina." (said at 0:27:40)

Published studies confirm that artificial intelligence and deep-learning models applied to retinal fundus photographs can predict coronary artery calcium (CAC) scores, incident cardiovascular disease, and stroke risk. Deep-learning algorithms have demonstrated discrimination of high CAC scores (>100) from zero CAC with an AUROC of approximately 0.83. Furthermore, systematic reviews and cohort studies show that retinal microvascular biomarkers and AI retinal models predict future cardiovascular events (such as myocardial infarction, cardiovascular mortality, and stroke) with predictive accuracy comparable to conventional clinical risk scores.

0:28:49supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Pericoronary arterial inflammation detected by AI analysis on CT angiography in the absence of arterial narrowing is associated with up to a 15-fold increased risk of heart attack.

"No, no, the Cleerly and the other ones in the US don't do this, but this is a a a Oxford, University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrow, it's, you know, you could have 15-fold risk of a heart attack." (said at 0:28:49)

The claim is supported by large prospective cohort data from University of Oxford researchers and the associated spinout technology (Caristo's AI-assisted perivascular Fat Attenuation Index [FAI] Score). In the ORFAN multicentre longitudinal cohort study published in The Lancet (2024), coronary inflammation measured by FAI Score on coronary CT angiography was evaluated in patients with and without obstructive coronary artery disease. Having high perivascular inflammation across coronary arteries was associated with a 12.6-fold increased risk of major adverse cardiac events (MACE, including myocardial infarction; HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold increased risk of cardiac mortality, independent of anatomical stenosis.

0:29:50supportedmoderateIt's Not Cholesterol. Inflammation Is What's Actually Causin

Adhering to comprehensive healthy lifestyle practices provides 7 to 10 additional years of life free from major age-related chronic diseases.

"show that if we practice the lifestyle factors that we've been reviewing with the details, um, that we we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:29:50)

A prospective analysis of 111,562 participants from the Nurses' Health Study and the Health Professionals Follow-Up Study investigated the impact of five low-risk lifestyle factors (a healthy diet, never smoking, ≥30 minutes/day of moderate-to-vigorous physical activity, moderate alcohol consumption, and a normal BMI). At age 50, women adhering to four or five healthy lifestyle factors had 34.4 years of life expectancy free of diabetes, cardiovascular disease, and cancer compared to 23.7 years for those with zero factors (a gain of 10.7 disease-free years). For men, the disease-free life expectancy at age 50 was 31.1 years versus 23.5 years (a gain of 7.6 disease-free years), directly supporting the claim of 7 to 10 additional years of life free from major chronic diseases.

0:31:12supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Clinical trial data demonstrate that the lower LDL cholesterol is reduced, the greater the cardiovascular protection.

"Well, if you look at all the data, the lower you go, the more protection" (said at 0:31:12)

Large meta-analyses of randomized controlled trials (such as the Cholesterol Treatment Trialists' Collaboration) and individual trial analyses (such as FOURIER and FOURIER-OLE) demonstrate a consistent, log-linear relationship where lower achieved low-density lipoprotein cholesterol (LDL-C) levels yield progressively greater reductions in major cardiovascular events, without a discernible lower threshold for clinical efficacy down to very low LDL-C levels (<20 mg/dL).

0:32:45supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Clinical data do not show that statins cause cognitive impairment or sexual dysfunction.

"Now, with respect to cognitive and, uh, sexual dysfunction, the data really don't show a hit there at all" (said at 0:32:45)

High-certainty evidence from randomized controlled trials and meta-analyses supports the claim that clinical data do not demonstrate a causal link between statin therapy and cognitive impairment or sexual dysfunction. A meta-analysis of individual participant data from 19 double-blind randomized trials encompassing 123,940 individuals found no evidence that statins cause cognitive impairment or other non-hepatic/non-muscular undesirable effects listed in product labels. Furthermore, systematic reviews and meta-analyses of randomized controlled trials evaluating lipid-lowering therapies (including statins) have found no significant association with neurocognitive disorders or global cognitive decline compared to placebo or control groups.

0:32:54supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

Alzheimer's disease accounts for 70% of dementia cases.

"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 0:32:54)

Epidemiological consensus establishes that Alzheimer's disease is the leading cause of dementia, accounting for an estimated 60% to 70% of all dementia cases globally.

0:34:00supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes.

"because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right? ... high doses of rosuvastatin, Crestor, or atorvastatin, Lipitor, that could also raise the risk of that person developing type 2 diabetes." (said at 0:34:00)

Large meta-analyses of randomized controlled trials demonstrate that statin therapy—and particularly intensive-dose or high-potency statin regimens such as high-dose atorvastatin and rosuvastatin—is associated with a modest, statistically significant increase in the risk of developing new-onset type 2 diabetes. A 2011 meta-analysis of 5 randomized trials (32,752 participants) comparing intensive-dose to moderate-dose statin therapy found a 12% increased odds of incident diabetes (OR 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years. This dose-dependent diabetogenic effect is well recognized, although guidelines emphasize that cardiovascular benefits generally outweigh this risk in indicated patients.

0:35:53supportedhighIt's Not Cholesterol. Inflammation Is What's Actually Causin

PCSK9 inhibitor injectable medications are not associated with an increased risk of diabetes.

"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes" (said at 0:35:53)

Extensive randomized controlled trial evidence and systematic reviews demonstrate that injectable PCSK9 monoclonal antibodies (such as evolocumab and alirocumab) do not increase the risk of new-onset diabetes or impair glycemic parameters (fasting plasma glucose, HbA1c), unlike statin therapy. A 2022 systematic review and meta-analysis of 32 trials comprising 65,861 participants evaluated this outcome with high certainty evidence and confirmed no increased risk of new-onset diabetes.

0:00:27supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Scientific data demonstrates that social isolation is an independent risk factor for neurodegenerative disease, cardiovascular disease, and cancer.

"There's so much data to show that that social isolation is a risk factor for neurodegenerative and cardiovascular and even cancer." (said at 0:00:27)

Large-scale prospective cohort studies and meta-analyses support the claim that social isolation is an independent risk factor associated with increased risks of neurodegenerative disease (such as dementia), cardiovascular disease, and cancer mortality. A 2023 meta-analysis of 90 prospective cohort studies comprising over 2.2 million individuals found that social isolation was significantly associated with elevated risks of cardiovascular disease mortality (pooled effect size 1.34) and cancer mortality (pooled effect size 1.24). Furthermore, a prospective cohort study of 462,619 UK Biobank participants demonstrated that social isolation independently increased the risk of incident all-cause dementia by 26% (hazard ratio 1.26) after adjusting for extensive demographic, biological, and socioeconomic covariates.

0:03:04supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Whole-genome sequencing of 1,400 individuals in the Welderly study (average age near 90 with no chronic illnesses) revealed almost no common protective genetic underpinnings.

"So it was called the Welderly study and it took seven years to find 1,400 people who were average age near 90 and up to 102 who had never had a chronic illness uh age-related or otherwise... we did whole genome sequencing on all of them and surprisingly we thought we'd find as you said all these genetic underpinnings and we found almost nothing." (said at 0:03:04)

Whole-genome sequencing of the Welderly cohort (healthy elderly individuals aged 80 and older who had never developed chronic diseases) demonstrated that healthy aging was not driven by distinct common longevity variants or an absence of rare pathogenic variants. While the investigators found modest reductions in polygenic susceptibility to Alzheimer's disease and coronary artery disease alongside suggestive loci related to cognitive preservation, the sequencing did not uncover definitive master protective genetic variants explaining their exceptional disease-free survival.

0:05:07supportedlowAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Multiple studies show that high polygenic disease risk can be neutralized by adopting healthy lifestyle factors.

"there are several studies I review in the book of polygenic risk uh and how that's neutralized by lifestyle factors." (said at 0:05:07)

Multiple large prospective cohort studies demonstrate that adhering to a healthy lifestyle (such as not smoking, regular physical activity, a healthy diet, and maintaining a healthy body weight) substantially offsets or attenuates the elevated risk conferred by high polygenic risk scores across multiple conditions, including coronary artery disease, stroke, and dementia. For example, a landmark study of over 55,000 participants published in The New England Journal of Medicine found that a favorable lifestyle was associated with a ~46–50% lower relative risk of coronary events among individuals in the highest quintile of genetic risk. Similar independent protective associations have been demonstrated for dementia and stroke in the UK Biobank. Under GRADE criteria, certainty is graded as low because the underlying evidence is observational.

0:07:40supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Proteomic analysis using up to 11,000 plasma proteins can determine eight distinct organ aging clocks, including brain, heart, liver, kidney, and immune system.

"these protein or proteomic scores where you take up to 11,000 plasma proteins and you get eight organ clocks including the immune system. So brain, heart, liver, kidney." (said at 0:07:40)

Large-scale plasma proteomic studies using high-throughput platforms (such as SomaScan assays measuring thousands of plasma proteins, up to 11,000 targets) have developed and validated organ-specific proteomic biological aging clocks. These models assess distinct biological age gaps across major organs and systems, including the brain, heart, liver, kidney, and immune system, and have demonstrated predictive validity for organ-specific disease onset and mortality in large human cohorts.

0:08:10supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

The UK Biobank is measuring proteomic profiles across 500,000 participants at a cost of approximately $50 per person, having already profiled over 50,000 individuals.

"and the biobank, UK Biobank is doing it for $50 for in 500,000 people. They've already done it in 50-some thousand." (said at 0:08:10)

The published record confirms that the UK Biobank Pharma Proteomics Project characterized plasma proteomic profiles for an initial phase of 54,219 participants ("50-some thousand"), as part of ongoing efforts to scale proteomic profiling across the broader UK Biobank cohort of 500,000 individuals.

0:10:12supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

The development of the three major categories of age-related diseases—most cancers, cardiovascular disease, and neurodegenerative disease—takes more than 20 years before clinical manifestation.

"The three major age-related diseases uh take more than 20 years. Uh cancer for almost all cancers, uh cardiovascular and certainly Alzheimer's neurodegenerative they take more than 20 years" (said at 0:10:12)

Scientific consensus across geroscience, oncology, cardiology, and neurology confirms that the preclinical development of the major chronic age-related diseases typically spans decades before clinical diagnosis. For neurodegenerative diseases such as Alzheimer's disease, biomarker and neuropathological studies demonstrate that pathological cascades (including amyloid-beta deposition and tau pathology) begin 20 or more years prior to symptom onset. Similarly, cardiovascular disease develops via atherosclerosis beginning in early life as fatty streaks that evolve over decades before resulting in acute events, and genomic/evolutionary modeling of common adult solid cancers indicates that initial driver mutations often precede clinical tumor manifestation by 15 to 30 years.

0:11:48supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Cardiovascular disease is 80% to 90% preventable through lifestyle, while cancer and neurodegenerative diseases are 40% to 50% preventable through lifestyle.

"cardiovascular is the most preventable of these three diseases. Um, 80 90%. Uh, our colleagues, uh, former colleagues from Cleveland Clinic came out with that's 90%, others 80%. But then cancer and neurodegenerative are 40 50% preventable through lifestyle." (said at 0:11:48)

Large-scale epidemiological studies and major consensus reports support these estimates. In cardiovascular disease, the landmark global INTERHEART study found that nine modifiable lifestyle and cardiometabolic risk factors accounted for 90% of the population attributable risk of myocardial infarction in men and 94% in women, with other major cardiovascular bodies commonly citing 80% to 90% preventability. For cancer, epidemiological analyses consistently estimate that 40% to 50% of incident cancer cases are attributable to modifiable lifestyle and environmental risk factors (such as tobacco use, diet, excess weight, alcohol, and physical inactivity). Similarly, major consensus bodies such as the Lancet Commission on dementia estimate that approximately 40% to 45% of dementia cases worldwide are attributable to modifiable lifestyle and health risk factors across the lifespan.

0:18:28supportedvery lowAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Researchers are actively using gene editing techniques to convert the APOE4 allele into APOE2 in animal models.

"there's a whole chapter in the book where people are editing APO turning APOE4 into APOE2 right now. I mean, ... In animals and you know, the idea of to do this in people that may happen someday" (said at 0:18:28)

Preclinical researchers are actively investigating genetic and gene-editing strategies to convert the high-risk APOE4 allele into protective or lower-risk variants such as APOE2 and APOE3 in animal models. For example, mouse models engineered for inducible allelic switching from APOE4 to APOE2 have demonstrated improvements in cerebral lipid profiles, reduction of amyloid pathology, and reversal of cognitive deficits. Additionally, CRISPR- and prime-editing platforms are being actively tested in vivo in humanized APOE4 mouse models to convert APOE4 toward lower-risk alleles.

0:28:55supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

The Alzheimer's Association diagnostic criteria categorize individuals with elevated plasma p-tau217 as having stage 1 Alzheimer's disease.

"And the American Alzheimer's Association, which I think has some problems, they're labeling people with p-tau217 as stage one Alzheimer's if it's elevated." (said at 0:28:55)

The revised criteria from the Alzheimer's Association Workgroup (Jack et al., 2024) establish a biological definition of Alzheimer's disease (AD) wherein disease onset occurs while individuals are asymptomatic. Under this framework, Core 1 biomarkers—specifically including accurate plasma biomarkers such as phosphorylated tau 217 (p-tau217)—are sufficient to establish a biological diagnosis of AD. Under the clinical staging framework, individuals who test positive for AD biomarkers but remain asymptomatic/cognitively unimpaired are categorized as having Stage 1 Alzheimer's disease.

0:39:20supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Slow-wave deep sleep is the specific sleep stage during which the brain clears toxic waste metabolites.

"the link between the deep sleep, which is when we get rid of the toxic waste metabolites in our brain, that's the time." (said at 0:39:20)

Mechanistic animal and human physiological studies demonstrate that sleep—particularly non-rapid eye movement (NREM) slow-wave deep sleep—substantially enhances the clearance of toxic metabolic waste products (such as amyloid-beta and tau) from the central nervous system via the glymphatic system. Preclinical work showed a dramatic expansion of the interstitial space and increased convective cerebrospinal fluid (CSF)-interstitial fluid exchange during sleep, and human neuroimaging confirmed that electrophysiological slow waves in NREM sleep drive large coupled waves of CSF flow responsible for waste clearance.

0:46:12supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

A multicenter Italian study found microplastics and nanoplastics in carotid artery plaques in over 60% of surgical patients.

"The big study from Italy, multiple centers, where they took the carotid artery plaque at the time of surgery and they looked to see if there was plastics, microplastics, nanoplastics in the artery plaque, and they found it in over 60% of people." (said at 0:46:12)

A prospective, multicenter Italian study published in the New England Journal of Medicine (Marfella et al., 2024) examined carotid artery plaque specimens retrieved during carotid endarterectomy. Among 257 patients with complete follow-up, polyethylene microplastics and nanoplastics were detected in 150 patients (58.4%), and polyvinyl chloride was detected in 31 patients (12.1%). Although the speaker slightly rounded up from 58.4% to 'over 60%', the core factual description of the multicenter surgical study and the detection rate is accurate.

0:46:41supportedlowAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Patients with microplastics detected in carotid artery plaques had a four- to five-fold increased risk of myocardial infarction, stroke, and all-cause mortality compared to those without plastics.

"And what was even worse is the people who had the plastics followed versus those who didn't have plastics in their in their plaque had a four to fivefold increase of heart attacks, strokes, and death compared to those without the plastic" (said at 0:46:41)

A prospective multicenter observational study published in The New England Journal of Medicine (Marfella et al., 2024) evaluated 257 patients undergoing carotid endarterectomy followed for a mean of 34 months. Patients with detectable microplastics and nanoplastics in their carotid atheromas had a 4.53-fold higher risk of experiencing the composite primary endpoint of myocardial infarction, stroke, or all-cause mortality compared to those without detectable plastics (hazard ratio 4.53, 95% CI 2.00 to 10.27, P < 0.001). As an observational cohort study, certainty is rated as low according to GRADE criteria.

0:51:47supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Cardiovascular disease is the leading cause of death worldwide and the leading cause of death among women.

"it's still the number one killer around the world, not just here. And it's still the number one killer in women who, you know, they think that it's breast cancer." (said at 0:51:47)

Global epidemiological surveillance data confirm that cardiovascular disease (CVD) is the leading cause of mortality globally as well as the leading cause of death among women worldwide. Comprehensive findings from the Global Burden of Disease Study 2023 estimated 19.2 million CVD deaths globally in 2023, making CVD the foremost cause of both mortality and disability-adjusted life years worldwide. Furthermore, the Lancet Women and Cardiovascular Disease Commission confirms that CVD remains the leading cause of death among women globally, accounting for substantially more female deaths than breast cancer or any other individual malignancy.

0:53:38supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases.

"and we've seen how that can prevent heart—preserve ejection fraction heart failure, which is half of all heart failure, right?" (said at 0:53:38)

Large-scale epidemiological studies and registries consistently indicate that heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% (and in some aging populations, more than half) of all heart failure cases.

0:54:20supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

AI analysis of retinal imaging can assess risk of coronary artery disease, stroke, and predict coronary artery calcium score.

"The retina also tells if you're going to have heart disease or a stroke in advance. It will even tell your calcium score of your heart arteries through your retina." (said at 0:54:20)

Deep-learning models applied to retinal fundus photographs have been developed and validated to predict coronary artery calcium (CAC) score categories and forecast cardiovascular disease (CVD) events, including stroke and coronary disease. In a study of 216,152 retinal photographs across cohorts from South Korea, Singapore, and the UK Biobank, a deep-learning algorithm predicting CAC (RetiCAC) achieved an AUROC of 0.742 for CAC presence and prognostic concordance comparable to CT-measured CAC scoring (c-index 0.71). Similarly, deep learning algorithms achieved an AUROC of 83.2% for discriminating no CAC from high CAC scores (>100) using bilateral fundus photographs.

0:55:45supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Pericoronary arterial inflammation detected by CT AI imaging without artery narrowing is associated with a 15-fold increased risk of myocardial infarction.

"This is a University of Oxford spinout. I think it's called Caristo. They're going to have that available soon. And I went through the data in the book. I mean, they've had multiple papers, but it's striking. If you have inflammation without a narrowing, you could have a 15-fold risk of a heart attack." (said at 0:55:45)

Evidence from large prospective and longitudinal cohort studies led by University of Oxford researchers (and commercialized via the spinout Caristo Diagnostics) supports the claim. In the ORFAN study of over 40,000 patients undergoing coronary computed tomography angiography (CCTA), perivascular fat attenuation index (FAI) Score—an AI-enabled imaging biomarker of pericoronary inflammation—predicted major adverse cardiac events (MACE, including myocardial infarction) and cardiac mortality independently of traditional risk factors and the presence of obstructive coronary artery disease. Specifically, individuals with high inflammation (top vs. bottom quartile FAI Score across all three coronary vessels) had a 12.6-fold higher risk of MACE (HR 12.6, 95% CI 8.5–18.6) and a nearly 30-fold higher risk of cardiac mortality (HR 29.8, 95% CI 13.9–63.9), demonstrating substantial risk even in the absence of obstructive arterial narrowing.

0:57:26supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Adherence to key healthy lifestyle factors extends healthy lifespan by 7 to 10 years free of major age-related chronic diseases.

"In the book, I found all these studies that I was really struck by that are recent that showed that if we practice the lifestyle factors that we've been reviewing with the details that we discussed, that gets us 7 to 10 years of healthy aging without one of these age-related diseases." (said at 0:57:26)

Large prospective cohort analyses directly support this statement. In a major prospective study analyzing data from the Nurses' Health Study (n=73,196) and the Health Professionals Follow-Up Study (n=38,366), adopting 4 to 5 low-risk lifestyle factors (never smoking, healthy weight/BMI, regular physical activity, moderate alcohol intake, and high diet quality) was associated with a 10.7-year increase in disease-free life expectancy (free of diabetes, cardiovascular disease, and cancer) at age 50 among women (34.4 vs. 23.7 years) and a 7.6-year increase among men (31.1 vs. 23.5 years) compared with individuals adhering to zero low-risk lifestyle factors.

1:00:15supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Alzheimer's disease accounts for approximately 70% of all dementia cases.

"and Alzheimer's, as you know, accounts for 70% of dementia" (said at 1:00:15)

Epidemiological data and major health organizations (including the World Health Organization and Alzheimer's Association) consistently report that Alzheimer's disease is the most common etiology of dementia, accounting for approximately 60% to 70% of all cases worldwide.

1:00:47supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Taking high-potency statin medications increases the risk of developing type 2 diabetes.

"When I wrote an op-ed in the New York Times like a decade ago and I called out the diabetes from statins, okay, because if you take a very potent statin, you have a higher risk of developing type 2 diabetes, right?" (said at 1:00:47)

High-quality randomized trial meta-analyses confirm that statin therapy—and higher-intensity or more potent statin regimens in particular—is associated with a modest but statistically significant increased risk of developing type 2 diabetes. A meta-analysis of five large randomized controlled trials (32,752 participants) comparing intensive-dose statin therapy to moderate-dose therapy found an increased risk of new-onset diabetes in the intensive-dose group (odds ratio 1.12, 95% CI 1.04–1.22), representing roughly 2.0 additional cases of diabetes per 1,000 patient-years.

1:01:18supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

High doses of potent statins like rosuvastatin and atorvastatin increase the risk of developing type 2 diabetes and elevating blood glucose levels.

"over the years, we've seen many more reports about the potent statins, high doses where you get a higher risk... if we're going to lower LDL and pull out all the stops and high doses of rosuvastatin (Crestor) or atorvastatin (Lipitor), that could also raise the risk of that person developing type 2 diabetes." (said at 1:01:18)

Extensive evidence from large randomized controlled trials and meta-analyses demonstrates that statin therapy, particularly intensive- or high-dose therapy with potent statins such as atorvastatin and rosuvastatin, is associated with a statistically significant, dose-dependent increase in the risk of incident (new-onset) type 2 diabetes.

1:02:34supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

PCSK9 inhibitor injectable drugs lower LDL effectively and are not associated with an increased risk of diabetes.

"the PCSK9 injectable drugs are a winner because they're potent and they have not been associated with diabetes, which is really interesting." (said at 1:02:34)

Large-scale systematic reviews and meta-analyses of randomized controlled trials (including major outcome trials such as FOURIER and ODYSSEY OUTCOMES) demonstrate that injectable PCSK9 inhibitors (such as alirocumab and evolocumab) markedly reduce LDL-C without significantly increasing the risk of new-onset diabetes mellitus compared with placebo or standard care.

1:07:41supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Approximately 12% of women will develop breast cancer in their lifetime, while 88% will not.

"Only 12% of women in their lifetime will ever have breast cancer. 88% will never develop breast cancer" (said at 1:07:41)

Population-based cancer registry data consistently demonstrate that the cumulative lifetime risk for a woman to develop invasive breast cancer is approximately 1 in 8 (roughly 12% to 13%), meaning approximately 87% to 88% of women will never develop the disease.

1:08:51supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Nearly 400,000 individuals have taken the Galleri multi-cancer early detection liquid biopsy test.

"The one that's used the most is Galleri of GRAIL. And almost 400,000 people have had that test." (said at 1:08:51)

Published real-world evidence and clinical trial data confirm substantial commercial and clinical use of GRAIL's Galleri multi-cancer early detection (MCED) test. Peer-reviewed real-world registries have documented more than 110,000 commercial tests in single cohorts (such as an analysis of 111,080 individuals published in 2025), which, combined with large-scale clinical trials (including the NHS-Galleri trial of ~140,000 participants) and continued commercial adoption, aligns with estimates approaching 400,000 tests administered.

1:08:51supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

When used in healthy adults age 50 and older, the detection rate of early-stage cancer with the Galleri test is approximately 2 per 1,000 people.

"The yield for that test is very low, and most of it is already late stage. Two out of a thousand you might pick up an early cancer." (said at 1:08:51)

In the prospective PATHFINDER study evaluating the Galleri multi-cancer early detection (MCED) blood test in 6,621 asymptomatic adults aged 50 years or older (PMID: 37805216), a cancer signal was detected in 92 participants (1.4%), leading to a confirmed cancer diagnosis (true positives) in 35 participants (~5.3 per 1,000 individuals screened). Approximately half of these confirmed cases were early-stage (Stage I–II) cancers, corresponding to an early-stage cancer detection rate of approximately 2 per 1,000 screened individuals.

1:10:54supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

A study using Danish and Veterans Affairs healthcare data showed that AI models analyzing electronic health records, including non-specific symptoms and normal-range laboratory trends, can identify elevated risk of pancreatic cancer earlier.

"We saw from the study that was done in Denmark and the VA for pancreatic cancer... they looked at a person's non-specific symptoms like, you know, abdominal symptoms for pancreatic cancer, and they saw ranges of liver function tests in the normal range, but trending in the wrong direction, right? So yeah, the AI picked up the higher risk" (said at 1:10:54)

A landmark 2023 study published in Nature Medicine applied deep learning models to electronic health record data from approximately 6 million patients in Denmark (Danish National Patient Registry) and 3 million patients in the United States (Veterans Affairs). The models analyzed sequences and trajectories of clinical disease codes—including early, non-specific abdominal symptoms and metabolic indicators—to predict pancreatic cancer occurrence up to 36 months before diagnosis (AUROC 0.88 in the Danish cohort; AUROC 0.78 upon retraining in the VA cohort), demonstrating that AI can identify individuals at substantially elevated risk for early surveillance.

1:16:28supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Men carrying BRCA gene mutations have a higher risk of prostate cancer and other forms of cancer.

"BRCA2, we as men, you know, a lot of us are carrying a BRCA gene just because we don't have breast cancer, you know, that means we have a higher risk of prostate cancer ourselves and other forms of cancer." (said at 1:16:28)

Male carriers of BRCA pathogenic variants, particularly BRCA2 mutations, have well-documented elevated risks of developing prostate cancer and certain other malignancies, such as pancreatic and stomach cancers. In prospective and familial cohort studies, men with BRCA2 mutations demonstrate a 3- to 5-fold higher risk of prostate cancer (with even higher relative risks below age 65) and a significantly increased incidence of aggressive, clinically significant disease compared to non-carriers, alongside elevated risks for pancreatic and gastrointestinal cancers.

1:20:53supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

Researchers at Johns Hopkins led by Bert Vogelstein developed a blood-based cancer screening test that combines protein biomarkers and circulating gene variants.

"Right. So, that's a Johns Hopkins, Bert Vogelstein effort. And that's right. As you said, they combined some key proteins that have been established as markers with some gene variants and made a relatively inexpensive test, and that's one that certainly has a potential as well." (said at 1:20:53)

Researchers led by Bert Vogelstein, Nickolas Papadopoulos, Kenneth Kinzler, and colleagues at Johns Hopkins University developed CancerSEEK, a multi-analyte blood test designed to detect eight common cancer types. The assay combines the assessment of circulating protein biomarkers with the detection of mutations in cell-free DNA (circulating tumor DNA). In a landmark study evaluating 1,005 patients with nonmetastatic cancers and 812 healthy controls, the test achieved a median sensitivity of 70% across the eight cancer types with greater than 99% specificity.

1:22:44supportedmoderateAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

AI analysis of standard mammogram images can predict a woman's risk of developing breast cancer up to five years in advance.

"There's a big study that showed that if you have AI analysis of a regular mammogram, you can predict cancer in that woman five years ahead if they're going to develop cancer." (said at 1:22:44)

Large retrospective cohort studies have validated deep learning algorithms (such as Mirai and related mammography-based AI models) that analyze standard screening mammograms to estimate future breast cancer risk up to five years in advance. In multi-institutional datasets from the United States, Sweden, and Taiwan, these AI risk prediction models achieved concordance indices (C-indices) ranging from 0.76 to 0.81 for 1- to 5-year risk assessment, significantly outperforming traditional clinical models such as the Tyrer-Cuzick and Gail models.

1:24:19supportedlowAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

CD19-targeted CAR-T cell therapy that depletes B cells has produced sustained remissions of severe autoimmune diseases like systemic lupus erythematosus and systemic sclerosis for over three years of follow-up.

"taking people with autoimmune diseases like lupus, systemic sclerosis, even multiple sclerosis, by giving them T cells, engineered T cells, CAR-T directed towards depleting their B cells, that when the B cells come back, they forgot that the person had disease... and for now three-some years of follow-up, they're cured of an autoimmune disease." (said at 1:24:19)

The spoken claim is supported by published clinical evidence evaluating CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with severe, treatment-refractory autoimmune diseases including systemic lupus erythematosus (SLE) and systemic sclerosis. Early trials, most notably a landmark study published in *The New England Journal of Medicine* by Müller et al. (2024), evaluated 15 patients with severe SLE, systemic sclerosis, or idiopathic inflammatory myositis following a single infusion of CD19 CAR T cells. Deep B-cell depletion was followed by B-cell repopulation, complete withdrawal of immunosuppressive drugs, and sustained drug-free remissions. Systematic synthesis of clinical studies demonstrates that sustained remissions across autoimmune rheumatic conditions extended up to 46 months (over three years) with follow-up. Because the underlying evidence consists of case series and non-randomized phase 1 trials without a control arm, certainty for the body of evidence is low despite the high magnitude of response observed.

1:34:07supportedhighAlzheimer's Starts 20 Years Before You Notice It — Here's Wh

The criteria for the 'Welderly' is individuals aged 80 and older who have no major age-related diseases.

"I just want to get to whatever age and stay as long as I can to meet that kind of Welderly criteria of 80-plus and no age-related major diseases that we've been discussing." (said at 1:34:07)

The 'Welderly' study (conducted by the Scripps Research Institute) specifically defined its healthy aging cohort as individuals aged 80 years and older who have reached late life without developing major chronic or age-related diseases (such as cardiovascular disease, cancer, diabetes, or dementia) and without requiring chronic medical interventions.

Fact-checked episodes

Publications